美股异动 | 再鼎医药(ZLAB.US)涨逾8% DLL3 ADC启动一线SCLC全球三期临床

智通财经
Sep 02
【美股异动 | 再鼎医药(ZLAB.US)涨逾8% DLL3 ADC启动一线SCLC全球三期临床】智通财经APP获悉,周三,再鼎医药(ZLAB.US)涨逾8%,报27.44美元。消息面上,8月31日,再鼎医药在Clinicaltrials.gov网站上注册了ZL-1310+PD-L1抗体一线治疗ES-SCLC的全球三期临床试验。该全球三期临床拟入组530例一线ES-SCLC患者,预计2030年6月初步完成。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10